激素受体阳性/人表皮生长因子受体2阴性早期及转移性乳腺癌的系统治疗
激素受体(HR)阳性/人表皮生长因子受体2(HER2)阴性乳腺癌占所有乳腺癌的65%-70%,发病率随年龄增长而增加。内分泌治疗是早期和晚期疾病的主要治疗手段,细胞周期蛋白依赖性激酶4/6抑制剂联合治疗可减少早期远处复发并改善转移性患者的总生存期。化疗根据分期和肿瘤生物学用于早期,晚期在内分泌耐药后使用,新型内分泌药物和抗体药物偶联物正在改变治疗格局。
要点
- HR阳性/HER2阴性乳腺癌占所有乳腺癌的65%-70%,发病率随年龄增长而增加。
- 内分泌治疗是早期和晚期HR阳性/HER2阴性乳腺癌的主要治疗手段。
- 细胞周期蛋白依赖性激酶4/6抑制剂联合治疗可减少早期远处复发并改善转移性患者总生存期。
核心结论
- 内分泌治疗是HR阳性/HER2阴性乳腺癌早期和晚期的主要治疗手段。
- 细胞周期蛋白依赖性激酶4/6抑制剂联合治疗可减少早期远处复发并改善转移性患者的总生存期。
- 新型内分泌药物和抗体药物偶联物正在改变治疗格局,需定义最佳治疗顺序以最大化临床获益并最小化毒性。
研究设计与样本
- 综述,讨论HR阳性/HER2阴性乳腺癌的病理和分子特征、内分泌耐药机制以及当前和新兴治疗。
主要发现
- HR阳性/HER2阴性乳腺癌占所有乳腺癌的65%-70%,发病率随年龄增长而增加。
- 细胞周期蛋白依赖性激酶4/6抑制剂联合治疗可减少早期远处复发并改善转移性患者的总生存期。
- 化疗根据分期和肿瘤生物学用于早期,晚期在内分泌耐药后使用。
- 新型内分泌药物和抗体药物偶联物正在改变治疗格局。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. HR-positive/HER2-negative breast cancer accounts for 65%-70% of all breast cancers, and incidence increases with increasing age. Treatment varies by stage, and endocrine therapy is the mainstay of treatment in both early stage and late-stage disease. Combinations with cyclin-dependent kinase 4/6 inhibitors have reduced distant recurrence in the early stage setting and improved overall survival in the metastatic setting. Chemotherapy is used based on stage and tumor biology in the early stage setting and after endocrine resistance for advanced disease. New therapies, including novel endocrine agents and antibody-drug conjugates, are now changing the treatment landscape. With the availability of new treatment options, it is important to define the optimal sequence of treatment to maximize clinical benefit while minimizing toxicity. In this review, the authors first discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data.
引用
- Huppert LA, Gumusay O, Idossa D, et al. Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. CA Cancer J Clin. 2023. PMID: 36939293. doi:10.3322/caac.21777
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。